Think your brain is too old to learn new tricks, let alone keep cognitive decline at bay? Think again. Research featured in the journal Cell Stem Cell in 2019 revealed that neurons continue to form in ...

Insights into the structures could lead to improved treatment strategies for transthyretin amyloidosis, a progressive, fatal disease in men.

Researchers have uncovered a link between COVID-19 and blood markers linked to faulty proteins in the brain. The analysis, ...

Individuals who had childhood epilepsy have an increased accumulation of brain amyloid later in life, potentially ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

Able to cross the blood-brain barrier, Xenon gas seemed to perk the mice right up, which began to become particularly active ...

ProMIS Neurosciences Inc., a clinical-stage biopharmaceutical company, made significant disclosures in its recent 8-K filing with the Securities and Exchange Commission. In its filing dated January 27 ...

The study indicated delayed REM sleep is a novel marker or risk factor for AD/ADRD pathogenesis. Throughout the study, Prolonged REML (rapid eye movement latency) was associated with higher amyloid ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.